MDMA-AT Neural Response

1	Evidence for altered neural activity patterns after MDMA-assisted therapy in adults with
2	chronic and severe post-traumatic stress disorder: a pilot study
3	
4	S. Parker Singleton ¹ , Julie B. Wang, M.P.H, Ph.D. ² , Michael Mithoefer, M.D. ^{2,3} , Colleen
5	Hanlon, Ph.D. ⁴ , Mark S. George, M.D. ^{3,5} , Annie Mithoefer ² , Oliver Mithoefer, M.D. ³ , Allison R.
6	Coker, Ph.D. ^{2,6} , Berra Yazar-Klosinski, Ph.D. ⁷ , Amy Emerson ² , Rick Doblin, Ph.D. ⁷ , Amy
7	Kuceyeski, Ph.D. ^{1,8}
8	
9	¹ Department of Computational Biology, Cornell University, Ithaca, NY 14850, USA
10	² MAPS Public Benefit Corporations, San Jose, CA 95117, USA.
11	³ Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina,
12	Charleston, SC 29425-0742, USA.
13	⁴ Wake Forest School of Medicine, Winston-Salem, NC 27101 USA
14	⁵ Ralph H. Johnson VA Medical Center, Charleston, SC 29425 USA
15	⁶ Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
16	⁷ Multidisciplinary Association for Psychedelic Studies, San Jose, CA 95117, USA.
17	⁸ Department of Radiology, Weill Cornell Medicine, New York, New York 10021, USA
18	
19	Corresponding Author: S. Parker Singleton; Email: sps253@cornell.edu
20	
21	For submission as an Original Article to the Frontiers in Psychiatry
22	Total word count = $<10,000$ words

MDMA-AT Neural Response

23	Role of Funding Sources: The clinical trial was sponsored by the Multidisciplinary Association
24	for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization. MAPS provided the
25	MDMA and fully funded this study from private and foundation donations. MAPS Public
26	Benefit Corporation (MAPS PBC), wholly owned by MAPS, was the trial organizer. SPS is
27	supported by the National Science Foundation Graduate Research Fellowship (Grant No. DGE-
28	1650441). AK is supported by the National Institutes of Health (RF1MH123232 and
29	R01NS102646).
30	Contributors: SPS and AK had full access to all the data in the study and take responsibility for
31	the integrity of the data and for the accuracy of the data analysis. BYK, AE, MM, RD conceived
32	and designed the clinical trial part of the study. MM & AM carried out experimental treatments
33	and recorded participant scripts. AE carried out sponsor oversight of data collection. CH and
34	MSG designed the imaging tasks and acquisition. CH, MSG, and OM oversaw the scanning and
35	data collection. SPS, AK, JW, AC drafted the paper. SPS carried out preprocessing, analysis, and
36	interpretation of data. RD obtained funding for the study. All authors contributed to the critical
37	review and final version of the manuscript.
38	Conflict of Interest: MM was paid as a contractor by MAPS PBC. AE, CP, AC, and JW
39	received salary support for full-time employment with MAPS PBC. BYK and RD received
40	salary support for full-time employment with MAPS. MM is on the Clinical Advisory Board of
41	Awakn Life Sciences.
42	Acknowledgements: The authors would like to thank the candidates who were willing to be
43	screened for eligibility; the participants in the trial who contributed their data; S. Sadler for her
44	dedication as the Study Coordinator; S. Braswell for serving as night attendant, M. Wagner and

45 J. Wymer for Independent Rater assessments. The authors would also like to thank: J. Holland

MDMA-AT Neural Response

46	who supported this trial as a Medical Monitor; L. Jerome for her numerous and varied
47	contributions to this Clinical Development Program since prior to its inception with global
48	systematic literature reviews and medical coding; C. Hennigan for data management; R.
49	Matthews and B. Shechet for clinical operations and monitoring; J. Sonstroem and A. Seltzer for
50	randomization support and system programming; E. Sola, Y. Gelfand, and B. Cohen for
51	conducting adherence ratings to facilitate standardization of therapy; I. Gorman for development
52	of adherence ratings; A. Wilens for supporting video recording. The authors would like to thank
53	Dr. Edmund Higgins for catalyzing the first discussions about acquiring imaging data in the
54	MAPS trial.

55

MDMA-AT Neural Response

5	7
J	1

ABSTRACT

58 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) for post-traumatic stress 59 disorder (PTSD) has demonstrated promise in multiple clinical trials. MDMA is hypothesized to 60 facilitate the therapeutic process, in part, by decreasing fear response during fear memory 61 processing while increasing extinction learning retention. The acute administration of MDMA in 62 healthy controls modifies recruitment of brain regions involved in the hyperactive fear response 63 in PTSD such as the amygdala and hippocampus. However, to date there have been no 64 neuroimaging studies aimed at directly elucidating the neural impact of MDMA-AT in PTSD 65 patients. We analyzed brain activity and connectivity via functional MRI during both rest and 66 autobiographical memory (trauma and neutral) response before and two-months after MDMA-67 AT for PTSD in nine veterans and first-responders. We find that MDMA-AT (i) increases 68 amygdala-hippocampal resting-state functional connectivity, and (ii) reduces amygdala-69 precuneus functional connectivity during neutral autobiographical memory recall in a manner 70 that co-varies with reduction of PTSD severity. These findings compliment previous research 71 indicating that amygdala-hippocampal functional connectivity is a potential target of MDMA-AT 72 and highlights other regions of interest related to memory processes. More research is necessary 73 to determine if these findings are specific to MDMA-AT compared to other types of treatment 74 for PTSD.

75

76 This study: NCT02102802 Parent-study: NCT01211405

MDMA-AT Neural Response

- 78 Keywords: PTSD, MDMA, amygdala, hippocampus, precuneus, symptom provocation,
- 79 retrosplenial cortex, dissociation, insula, fMRI, functional connectivity, resting-state,
- 80 autobiographical memory.

MDMA-AT Neural Response

81 **1. INTRODUCTION**

82 Post-traumatic stress disorder (PTSD), which can arise following exposure to a traumatic event 83 or repeated stressful events, impacts hundreds of millions of people, and is a debilitating social 84 and economic burden on individuals and their families. PTSD is associated with an increased fear response (VanElzakker, Staples-Bradley, and Shin 2018) and distressing and intrusive re-85 86 experiencing of traumatic memories (Ehlers 2010) that often serves as a barrier to the therapeutic 87 process. Current psychological therapies for PTSD have high dropout rates (Goetter et al. 2015), 88 especially trauma focused therapies (Lewis et al. 2020). When presented with trauma-related 89 stimuli, PTSD patients have shown increased activation in the precuneus, retrosplenial cortex, 90 anterior cingulate cortex (ACC), and amygdala compared to neutral stimuli (Sartory et al. 2013), 91 suggesting augmented recruitment of brain regions involved in self-referential processing 92 (Cavanna and Trimble 2006), salient autobiographical memory (Svoboda, McKinnon, and 93 Levine 2006; Spreng, Mar, and Kim 2009; Sestieri et al. 2011; Maddock 1999), and fear and 94 emotion (LeDoux 2003).

95

96 3.4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) is hypothesized to reduce 97 the fear response associated with re-experiencing traumatic memories, and therefore may 98 facilitate tolerable processing of traumatic content in patients with PTSD (Mithoefer et al. 2011). 99 Phase 2 and 3 trials have demonstrated promise for MDMA-AT as a viable treatment for PTSD 100 (Mitchell et al. 2021; Mithoefer et al. 2019; Wang et al. 2021; Jerome et al. 2020). In healthy 101 individuals, acute administration of MDMA has been shown to enhance positive and reduce 102 negative affect during the recollection of autobiographical memories, while preserving vividness 103 and emotional intensity (Carhart-Harris et al. 2014). In another study, MDMA was found to

MDMA-AT Neural Response

104	preserve the memory accuracy when administered during both encoding and retrieval phases,
105	while attenuating the recollection of salient details for both positive and negative memories,
106	suggesting that MDMA alters emotional memory representations (Doss et al. 2018). Again in
107	healthy controls, MDMA was found to enhance fear extinction retention rates compared to
108	placebo when administered during extinction training phases (Maples-Keller et al. 2022). These
109	findings suggest that MDMA may aid the therapeutic process, in part, by enabling patient access
110	to emotionally challenging material and facilitating memory reconsolidation/fear extinction
111	processes (Feduccia and Mithoefer 2018).
112	
113	The exact neurobiological underpinnings of PTSD and the specific effects of MDMA-AT in
114	individuals with PTSD have not been fully characterized, but several studies suggest the
115	amygdala and hippocampus play an important role. The amygdala is broadly associated with fear
116	response, and the hippocampus, associated with learning and memory, may provide contextual
117	information necessary for cognitive-affect during memory recall (LeDoux 2003; Harnett,
118	Goodman, and Knight 2020; Pitman et al. 2012). Sripada et al. (2012) found combat veterans
119	with PTSD have decreased amygdala-hippocampal resting-state functional connectivity (RSFC)
120	compared to combat veterans without PTSD, which the authors speculate may represent an
121	inability to contextualize affective information in PTSD. In healthy volunteers, the acute
122	administration of MDMA has the reverse effect, namely, increased amygdala-hippocampal
123	RSFC (Carhart-Harris, 2015). Despite evidence that RSFC between the amygdala and
124	hippocampus is implicated in PTSD and that this connection may be modulated by MDMA, no
125	study to date has shown relationships between changes in these regions' functional connectivity
126	and the therapeutic effects of MDMA-AT.

MDMA-AT Neural Response

127

128	Herein, we describe results from a study of combat veterans and first-responders undergoing
129	MDMA-AT for PTSD in a randomized, double-blind, dose-response phase 2 clinical trial
130	(Mithoefer et al. 2018). Both resting-state and task-fMRI data, acquired while individuals
131	listened to a trauma-related or neutral script, were collected before and two months after
132	MDMA-AT (follow-up scans were collected after the blind was broken). Prior to analysis, we
133	hypothesized that MDMA-AT would increase RSFC between the amygdala and hippocampus
134	(Sripada et al. 2012; Carhart-Harris et al. 2015). We further hypothesized that, at baseline, brain
135	activity would be higher during the trauma-related listening task compared with the neutral
136	listening task in regions associated with autobiographical memory, fear, and emotion, such as the
137	precuneus, retrosplenial cortex, ACC, and amygdala, and that this effect would be reduced post-
138	treatment (Sartory et al. 2013). Finally, we hypothesized that the magnitude of the pre-to-post
139	treatment change in the functional connectivity of the amygdala and hippocampus would be
140	correlated with the magnitude of change in the pre-to-post treatment Clinician-Administered
141	PTSD Scale (CAPS-IV) total severity scores (Blake et al. 1990). Understanding the
142	neurobiological mechanisms of PTSD and how we may modulate these mechanisms is
143	imperative to developing effective, personalized treatments to reduce the burden of this disease.
144	

145 **2. METHODS**

MDMA-AT Neural Response



147 Figure 1: Study design. Subjects were assessed and imaged at the start of the study 148 (baseline). All subjects (low dose (LD), medium dose (MD), and high dose (HD)) underwent 149 three non-drug preparatory therapy sessions prior to their first MDMA dosing session. Each 150 MDMA session was followed by three non-drug integration therapy sessions. After MDMA 151 Session 2 and the subsequent integration sessions, subjects were assessed and the dosing 152 blind was broken. HD subjects completed their final set of drug and non-drug therapy 153 sessions unblinded, and LD/MD subjects crossed over into the HD arm where they 154 completed three sets of drug and non-drug sessions, now with the higher dose and unblinded. 155 All subjects were assessed and underwent MRI approximately two months following their 156 last HD MDMA session. 157

158 2.1 Trial design

146

159 The present study analyzed data from a sub-study (NCT02102802) of a Phase 2 randomized,

160 double-blind, dose-response trial of MDMA-AT in veterans and first responders with severe and

161 chronic PTSD (NCT01211405) (Mithoefer et al. 2018). A detailed study description of the

MDMA-AT Neural Response

162	parent study can be found in (Mithoefer et al. 2018), here we summarize the study design.
163	Participants were recruited and screened between November 10, 2010 and January 29, 2015.
164	Veterans and first responders with severe PTSD as measured by a Clinician-Administered PTSD
165	Scale (CAPS-IV) (Blake et al. 1990) total severity score of 50 or more were enrolled in the study
166	and received three 90-minutes preparatory therapy sessions. In Stage 1, participants were
167	randomly assigned to three groups (1:1:2) that received blinded 30, 75 or 125 mg MDMA HCl
168	(followed by a supplemental half-dose unless withheld or declined) with therapy in two 8-hour
169	dosing sessions. Each of the dosing sessions was followed by three non-drug 90-minute follow-
170	up integration sessions that were one month apart. Psychological assessments were collected at
171	baseline and the primary endpoint which was one month after the second dosing session. In
172	Stage 2 of the study, the blind was broken and participants originally in the HD (125 mg) group
173	participated in a final open-label session at the same dose, while participants originally in the LD
174	(30 mg) or MD (75 mg) groups participated in three HD ($100 - 125 mg$) open-label sessions.
175	Each dosing session in Stage 2 was followed by three non-drug 90-minute integrative sessions.
176	Psychological assessments were collected approximately 2 months and 12 months after the final
177	dosing session in Stage 2. Psychological assessment included the clinician-administered
178	measures CAPS-IV and Global Assessment of Functioning (GAF; general psychological
179	function; Guze 1995), and self-reported measures including Beck Depression Inventory-II (BDI-
180	II; depression symptoms; Beck et al. 1996), Pittsburgh Sleep Quality Index (PSQI; sleep quality;
181	Buysse et al. 1989), Post-Traumatic Growth Inventory (PTGI; perceived growth following
182	trauma; Tedeschi and Calhoun 1996), and the Dissociative Experiences Scale II (DES-II;
183	symptoms of dissociation; Carlson and Putnam 1993).

MDMA-AT Neural Response

184	Participants in the parent study were able to opt into the MRI-based sub-study after which they
185	provided written informed consent approved by the Medical University of South Carolina
186	Institutional Review Board. They were screened for additional neuroimaging related eligibility
187	criteria and were excluded for any conditions that could render MRI unsafe. Following baseline
188	CAPS-IV assessment in the parent study, sub-study participants worked with investigators to
189	create two scripts: one describing a personally traumatic event and one reflecting their typical
190	morning routine at home. Two audio recordings, each six minutes in length, were created from
191	the participant's reading of each script. Each audio recording was divided into two 3-minute
192	blocks for the task-fMRI. All participants were imaged at baseline, prior to therapy, and again at
193	the follow-up visit two months after their final dosing session. LD (N = 2) and MD (N = 2)
194	participants were additionally imaged after the primary endpoint visit in Stage 1 (one month
195	following their second dosing session), however the small sample sizes prevented any
196	meaningful analysis with these scans. The present analysis focuses on the pre- and post-therapy
197	effects of MDMA-AT on fMRI biomarkers, and thus uses the scans collected at pre-treatment
198	(baseline) and at least 2 months after the largest dose of MDMA (follow-up).
199	

200 2.2 MRI acquisition

At each scanning session, participants underwent MRI on a 32 channel 3T Siemens system. T1 anatomical scans with TR/TE=1900/2.34 ms and $0.9 \times 0.9 \times 1.0$ mm voxel size were collected, followed by two identical task fMRI (design described below) (TR/TE = 2200/35ms, 3.0 mm isotropic voxel size, length of each scan = 14:25 min) and one resting state fMRI (TR/TE = 2000/30ms, 3.3x3.3x3.0 mm voxel size, length = 5:00 min).

MDMA-AT Neural Response

206	Participants' 6-minute trauma and neutral audio scripts were divided into two three-minute
207	trauma and neutral blocks each (See 2.1 Trial design for description of audio recordings). During
208	fMRI, participants were presented with the visual cue "allow" and instructed to allow themselves
209	to experience the scripts as their audio recordings were played for both neutral and trauma
210	blocks. Each task scan had an alternating block design (neutral 1, trauma 1, neutral 2, trauma 2)
211	with an 18 second 'rest' period at the start of the scan and between each block, and about a
212	minute of rest at the end of the scan. The precise length of each audio block was 2.95 min.
213	
214	2.3 Image preprocessing
215	FreeSurfer (Dale, Fischl, and Sereno 1999) was applied to the T1s to create white matter (WM),
216	gray matter (GM) and cerebrospinal fluid (CSF) segmentations. FMRIB Software Library (FSL)
217	(Smith et al. 2004) was used for 1) brain extraction, 2) registration between T1s and fMRI's
218	(brain-boundary registration, non-linear, full-search), 3) high-pass filtering 4) slice-time and 5)
219	motion correction.
220	
221	2.4 Activation analysis: brain response to trauma versus neutral audio listening
222	FSL's FEAT tool (Woolrich et al. 2004) was used for fitting a general linear model (GLM) to the
223	voxelwise timeseries for each task scan after spatial smoothing using a Gaussian kernel function
224	(6 mm full width at half maximum (FWHM)). We constrained our search to four bilateral
225	regions of interest (ROIs) in PTSD symptom provocation (Sartory et al. 2013) using the
226	Desikan-Killiany atlas (Desikan et al. 2006): the precuneus, isthmus cingulate (containing the
227	retrosplenial cortex), rostral anterior cingulate, and amygdala. For 1st- level analysis, models
228	were generated for the neutral block, the trauma block, and a contrast of the two (trauma >

MDMA-AT Neural Response

229	neutral). Confound explanatory variables (EVs) included the temporal derivative of each block, 5
230	nuisance regressors each for WM and CSF signal, and 6 directions of motion (x/y/z mm/rad).
231	Second-level analysis averaged the models from each of the two task scans performed at each
232	time point. Third-level analyses, using a two-sided, one-sample t-test (FSL randomize; Winkler
233	et al. 2014) identified group-level response for the contrast model (i) at baseline, and (ii) at the
234	two-month follow-up. A final third-level analysis (iii) compared the group-level responses to the
235	contrast model at baseline and follow-up using a two-sample, two-sided, paired t-test (FSL
236	randomize; Winkler et al. 2014). Third-level results were corrected for multiple comparisons
237	using threshold-free cluster enhancement (TFCE; $p < 0.05$) (Smith and Nichols 2009).
238	
239	2.5 Functional connectivity
240	Functional connectivity here is defined as the statistical relationship (in this case Pearson
241	correlation) between two brain regions' blood-oxygen level dependent (BOLD) time series
242	extracted from fMRI scans.
243	Prior to extraction of functional connectivity, in addition to the preprocessing steps taken in 2.3,
244	fMRI data were further denoised using an in-house pipeline
245	(https://github.com/kjamison/fmriclean). FMRIs were bandpass filtered and regressed for 24
246	motion confounds (Friston et al. 1996), 5 nuisance regressors each for WM and CSF, and one for
247	global GM signal. The first five frames (scanner start-up noise) and confound frames were
248	discarded. Gray matter was further parcellated into 68 cortical and 16 subcortical regions of
249	interest (ROIs) (Desikan et al. 2006). The cerebellum was excluded due to incomplete scan
250	coverage of this structure.

MDMA-AT Neural Response

251	In the pre-hoc analysis of the resting-state fMRI data, resting-state functional connectivity
252	(RSFC) between the right and left amygdala and right or left hippocampus was evaluated. One-
253	tailed, paired <i>t</i> -tests were used to compare the 4 RSFC measures before and after MDMA-AT.
254	Functional connectivity during task fMRI between the four regions of interest (bilateral
255	amygdala and hippocampus) and the rest of the brain was assessed. This was done with the time-
256	series extracted from the (a) neutral block and (b) trauma block, separately. See the
257	Supplemental Information for functional connectivity analysis using the entire scan. Group-level
258	changes from pre- to post-therapy in the strength of functional connections were assessed using
259	two-tailed, paired <i>t</i> -tests.
260	After obtaining whole-brain activation and functional connectivity results from the task data,
261	which highlighted the precuneus as a region of interest, we performed a post-hoc analysis of the
262	RSFC between both amygdalae and hippocampi with the right and left precuneus. We used two-
263	tailed, paired <i>t</i> -tests to compare the 8 RSFC measures before and after MDMA-AT.
264	Pearson correlations were calculated between individuals' changes in functional connection
265	strength and change in CAPS-IV total severity scores (follow-up – baseline). All <i>p</i> -values were
266	corrected for multiple comparisons using the Benjamini-Hochberg algorithm (Benjamini and
267	Hochberg 1995) where indicated.
268	
269	
270	3. RESULTS

271 3.1 CAPS significantly decreases after HD MDMA-AT

272 Ten participants enrolled in the sub-study, and one withdrew consent after baseline due to

anxiety in the MRI scanner, leaving nine participants with MRI data at both time points (6 male,

MDMA-AT Neural Response



- 275 participants self-reported moderate depression as indexed by BDI-II (Beck et al. 1996). One
- 276 subject's baseline resting-state fMRI was truncated due to technical issues, leaving eight subjects
- 277 for resting-state analysis and nine for the task fMRI analysis. Mean (SD) CAPS-IV total severity
- scores of the nine individuals pre- and post-MDMA-AT were 86 (\pm 16) and 39 (\pm 25),
- 279 respectively, representing a significant decrease in PTSD symptom severity between the two
- time points (Figure 2; N=9, t = 6.36, p = 0.00022). The average percent decrease in CAPS was
- 281 57 (\pm 26)%. Results on all participants enrolled in the Phase 2 parent trial have been previously
- 282 reported (Mithoefer et al. 2018).
- 283



MDMA-AT Neural Response

- Figure 2: Patient CAPS-IV total severity scores at the baseline (pre-therapy) and two-month
- 286 follow-up (post-therapy) scanning sessions. Black and red lines indicate group means and
- 287 medians, respectively. A significant reduction is PTSD severity was observed after MDMA-AT
- 288 (baseline > follow-up; N=9, *t* = 6.36, p = 0.00022).
- 289

290 **3.2** Amygdala-hippocampal RSFC increases after HD MDMA-AT

- 291 The RSFC was assessed between the amygdala and hippocampus before and after MDMA-AT
- and the strengths of these connections are illustrated in Figure 3. All connections trended
- 293 towards increased functional connectivity after therapy compared to before therapy (using a one-
- sided paired t-test), with left amygdala to both hippocampi having significant increases (t = -
- 295 2.97, uncorrected p = 0.0104, pFDR = 0.0416 and t = -2.11, uncorrected p = 0.0361, pFDR =
- 296 0.0722 for left and right hippocampus, respectively. N=8).

MDMA-AT Neural Response



297

Figure 3: RSFC between the amygdala and hippocampus before and after MDMA-AT. P-values from a one-sided, paired t-test have been corrected for multiple comparisons. Black and red lines indicate group means and medians, respectively. (N = 8; t-statistics indicate baseline > followup; * uncorrected p < 0.05, ** pFDR < 0.05).

302

303 Individual-level pre-to-post-therapy changes between the strength of these functional

304 connections were then correlated with changes in CAPS scores. All four correlations showed that

MDMA-AT Neural Response

305	larger increases in connectivity strength after therapy were associated with larger reductions in
306	symptom severity (improvement in PTSD). Only one of these (right amygdala to left
307	hippocampus) was significant before correction (N = 8; R = -0.773, uncorrected p = 0.0244 ,
308	pFDR = 0.0976).
309	

310 3.3 Increased precuneus and retrosplenial cortex activation during symptom provocation 311 We compared script-driven activations (trauma > neutral) in four pre-determined ROIs: the 312 bilateral precuneus, isthmus cingulate (anatomical gyrus containing the retrosplenial cortex), 313 rostral anterior cingulate cortex (ACC), and amygdala (Figure 4A). These regions have 314 previously been shown to activate more during trauma-related stimuli than neutral stimuli in 315 PTSD patients (Sartory et al. 2013). Before therapy, there tended to be stronger responses to the 316 trauma script versus the neutral script in our ROIs, as evidenced by the generally positive t-317 statistics (Figure 4B). After correction using threshold free cluster enhancement (TFCE), there 318 was significantly greater activation during the trauma scripts compared to the neutral scripts in a 319 cluster on the border of the bilateral precuneus and bilateral isthmus cingulate/retrosplenial 320 cortex (Figure 4B, black outline; N=9, cluster corrected, p<0.05). After therapy, there was less 321 contrast between the two scripts, and no significant clusters (Figure 4C). Finally, we assessed the 322 differences in the contrast model before and after therapy (baseline > follow-up). There was 323 generally greater (positive) contrast between the trauma and neutral scripts at baseline than at 324 follow-up, however no clusters survived correction for multiple comparisons (Figure 4D).

MDMA-AT Neural Response



327 Figure 4: Group-level activation contrasts for trauma versus neutral script listening tasks. (A) 328 Results were constrained to four bilateral anatomical ROIs from PTSD symptom provocation 329 literature (Sartory et al. 2013): the precuneus, isthmus cingulate (retrosplenial cortex), rostral 330 anterior cingulate cortex (ACC), and the amygdala (Desikan et al. 2006). Panels B, C, & D show 331 the t-statistic from the corresponding comparison. (B) Pre-therapy there is a significant cluster 332 within the bilateral precuneus/isthmus cingulate (outlined in black; center of gravity: MNI -1, -333 51, 28, 60 voxels (1620 mm³), peak z-value = 2.89; p < 0.05, cluster corrected; N = 9). (C) There 334 were no significant activation contrast clusters after therapy. (D) Comparing the group-level 335 contrasts between time points (baseline > follow-up), there were no clusters that met significance 336 thresholds after correction.

337

326

338 **3.4 MDMA-AT** associated changes in task functional connectivity

We compared the pre- and post-therapy strength of amygdalae and hippocampal functional connections with the rest of the brain during the neutral and trauma blocks separately (Figure 5A/B). There were several connections with a trend for change from pre- to post-therapy (SI

MDMA-AT Neural Response

- 342 Tables 1 and 2). After correction for multiple comparisons, the left hippocampus and left caudal
- 343 middle frontal gyrus functional connectivity during trauma recall was significantly reduced at the
- 344 two-month follow-up post-therapy (N = 9, t = 7.13, pFDR = 0.0082).



345

Figure 5: Paired t-statistics shown for differences in functional connectivity between all brain
regions and the amygdalae and hippocampi during (A) neutral memory audio listening and (B)
trauma memory audio listening (N = 9; baseline > follow-up; * two-tailed p < 0.05, uncorrected;
** pFDR < 0.05, corrected).

350

Individual-level pre-to-post therapy changes in the functional connections calculated in the previous section were then correlated with the individual-level reductions in CAPS scores (Figure 6). Many significant correlations (corrected and uncorrected) were positive, meaning that larger reductions in connectivity from pre- to post-therapy corresponded to larger improvements in PTSD symptomology (SI Tables 3 and 4). Following correction for multiple comparisons, the

MDMA-AT Neural Response

- 357 two positive correlations between changes in right amygdala and bilateral precuneus connectivity
- during neutral memory recall and CAPS scores remained significant (Figure 6C).



359

Figure 6: Pearson correlation values between changes in each functional connection during (A)
neutral memory audio listening and (B) trauma memory audio listening and changes in CAPS
scores. (C) Scatter plots of the significant correlations from the neutral condition (N = 9; followup – baseline; * p-value < 0.05, uncorrected; ** pFDR < 0.05, corrected).

MDMA-AT Neural Response

365

366 **3.4 Post-hoc analysis of amygdala and hippocampus RSFC with the precuneus**

367 As change in the task-based functional connectivity between the amygdala and precuneus was 368 found to be related to improvement of PTSD severity scores, we performed post-hoc analyses of 369 RSFC between the precuneus and amygdalae and hippocampi to identify 1) any changes before 370 and after therapy and 2) any correlations between change in functional connectivity and change 371 in CAPS. We did not find any pre- and post-therapy changes in functional connection strength of 372 amygdalae or hippocampi with the precuneus. Pre-to-post therapy changes in the RSFC between 373 the right amygdala and both the right and left precuneus correlated with the reductions in CAPS 374 scores, albeit at a trend level (N = 9; R = 0.687, uncorrected p = 0.0599; R = 0.667, uncorrected p 375 = 0.0709 for the right and left precuneus, respectively), reflecting the task-based functional 376 connectivity finding during the neutral block.

377

378 **3.5** Correlations with other outcome measures

379 Although not the primary focus of our analysis, we also repeated the previous correlations using 380 other secondary outcome measures in place of CAPS-IV total severity scores. Namely, changes 381 between baseline and follow-up in the BDI-II (depression symptoms), the PSQI (sleep quality), 382 the PTGI (perceived growth following trauma), the DES-II (symptoms of dissociation), and the 383 GAF (general psychological function) were used. Following correction for multiple 384 comparisons, only three correlations remained significant and, notably, all three were between 385 changes in task functional connectivity and symptoms of dissociation. During the neutral task, 386 reduction in functional connectivity between the left hippocampus and the left pre- and post-387 central gyrus (motor) at follow-up compared to baseline correlated with reductions in

MDMA-AT Neural Response

388	dissociative symptoms (lower DES-II scores; pre-central: $R = 0.930$, pFDR = 0.0226; post-
389	central: $R = 0.904$, pFDR = 0.0346). During the trauma task, reduction in functional connectivity
390	between the right amygdala and right insula at follow-up compared to baseline correlated with
391	reduction in dissociative symptoms ($R = 0.925$, pFDR = 0.029).
392	
393	DISCUSSION
394	We report signatures of brain response during rest and audio listening task in eight veterans and
395	one first-responder with clinically diagnosed chronic and severe PTSD before and two-months
396	after MDMA-assisted therapy. We found a significant reduction in CAPS-IV total severity
397	scores after therapy, indicating our sub-study participants mirrored the results from the parent
398	study (Mithoefer et al. 2018). RSFC between the amygdala and hippocampus was significantly
399	strengthened post-therapy, providing more evidence that modulation of amygdalae-hippocampal
400	RSFC may be an important component of MDMA-AT for PTSD (Sripada et al. 2012; Carhart-
401	Harris et al. 2015). We also found participants had increased activation in the
402	precuneus/retrosplenial cortex while listening to traumatic versus neutral memory narrations pre-
403	therapy, and that no significant contrast existed after MDMA-AT (the comparison between the
404	two time points was also not significant). Finally, the pre- to post-therapy reduction in functional
405	connectivity between the right amygdala and right precuneus during neutral memory audio
406	strongly and significantly correlated with PTSD symptom improvement.
407	
408	Previous work quantifying functional connectivity in PTSD (Sripada et al. 2012) and acute
409	MDMA administration in controls (Carhart-Harris et al. 2015) suggests one mechanism of
410	MDMA-AT may be to increase pathologically lowered amygdala-hippocampal RSFC (Feduccia

MDMA-AT Neural Response

411	and Mithoefer 2018). The amygdala is associated with fear expression, threat recognition, and
412	heightened response to emotional memories and is often dysregulated in patients with PTSD
413	(LeDoux 2003; Pitman et al. 2012; Liberzon et al. 1999; Etkin and Wager 2007; Bremner et al.
414	2005; Harnett, Goodman, and Knight 2020). The hippocampus also plays a central role in PTSD
415	as it is thought to provide contextual information important for cognitive-affect during memory
416	recollection (Harnett, Goodman, and Knight 2020; Pitman et al. 2012). Sripada et al (2012)
417	found combat veterans with PTSD had reduced amygdala-hippocampal RSFC compared to
418	combat-exposed controls, leading them to speculate that this may relate to an inability to
419	contextualize affective information in PTSD. Carhart-Harris et al (2015) demonstrated that
420	amygdala-hippocampal RSFC is increased acutely in MDMA administration compared to
421	placebo and this increase occurred in a manner that correlated with the drug's subjective effects
422	at a near-significant level, leading these researchers to propose that this functional connection
423	was a primary target of MDMA-AT. Prior to our analysis (although after the study was designed
424	and the data collected), we hypothesized that the RSFC between the amygdala and hippocampus
425	would be higher after MDMA-AT compared to pre-therapy levels, which we confirmed. We also
426	found that the amount of increased amygdala-hippocampal RSFC after MDMA-AT positively
427	correlated with PTSD symptom improvement at a near-significant level. Our current findings
428	provide further evidence that one mechanism driving MDMA-AT's treatment of PTSD could be
429	an increase in amygdala-hippocampus RSFC.

430

We next sought to study brain-response during autobiographical memory listening to draw
additional conclusions about MDMA-AT's effects in individuals with PTSD. Before therapy,
participants had larger activation in a cluster of voxels located in the bilateral precuneus and

MDMA-AT Neural Response

434	retrosplenial cortex during an individualized trauma script listening task compared to neutral
435	audio script listening. The precuneus is involved in self-processing operations (e.g. first-person
436	perspective taking), episodic memory retrieval, and visual-spatial imagery (Cavanna and Trimble
437	2006). Its activation is often correlated with activation of the retrosplenial cortex (Cauda et al.
438	2010), which is implicated in autobiographical memory recollection (Svoboda, McKinnon, and
439	Levine 2006; Spreng, Mar, and Kim 2009). The retrosplenial cortex is also found to be
440	consistently activated by emotionally salient stimuli, and has been proposed to play a role in the
441	interaction between emotion and memory (Maddock 1999). We conjecture that increased
442	activation in these regions during traumatic compared to neutral audio listening (Figure 4B)
443	could be related to an increased intensity of the recollection or re-experiencing of traumatic
444	memories compared to neutral ones for patients before therapy. At 2-month follow-up to
445	MDMA-AT, there was no significant difference in the trauma vs neutral script activation of this
446	area (Figure 4C). Although the longitudinal comparison of these two time points also showed no
447	significant difference after correction for multiple comparisons, the positive t-statistics indicate
448	that the contrast between trauma and neutral was generally larger at baseline, particularly in the
449	precuneus/retrosplenial cortex and the anterior cingulate cortex (ACC) (Figure 4D). Larger
450	studies may allow more statistical power to identify longitudinal differences if they do indeed
451	exist. These findings are consistent with previous studies — a meta-analysis by Sartory et al
452	(2013) (the source of our ROIs) found that PTSD patients had greater activations in the
453	precuneus and retrosplenial cortex, as well as the bi-lateral amygdala and anterior cingulate
454	cortex during trauma-related stimuli compared to neutral stimuli. In addition, other longitudinal
455	studies of individuals with PTSD have found the amount of decrease in precuneus/posterior
456	cingulate cortex (PCC; of which the isthmus cingulate/retrosplenial cortex is a part) activation

MDMA-AT Neural Response

457	during symptom provocation at the end of study to be correlated with amount of reduction in
458	symptom severity (Garrett et al. 2019; Ke et al. 2016).

459

460 PTSD is often associated with hyperactivity in the amygdala (Pitman et al. 2012); the acute

461 administration of MDMA in healthy volunteers decreases blood flow to the amygdala during rest

462 (Carhart-Harris et al. 2015) and attenuates its response to angry faces (Bedi et al. 2009). We had

463 hypothesized that we would observe hyperactivity of the amygdala to trauma versus neutral

464 scripts at baseline and that MDMA-AT would attenuate this response, however we observed

465 neither. It is important to note inconsistencies in the literature here. Amygdala hyperactivity in

466 PTSD is not always observed, possibly due to differences in subtypes, sex, cultural

467 representations, or choice of paradigm (van Huijstee and Vermetten 2018; Lanius et al. 2001;

468 Lanius et al. 2002; Helpman et al. 2021; Chiao et al. 2008; Liddell and Jobson 2016).

469 Additionally, while MDMA did suppress amygdala activity during rest and in response to angry

470 faces as previously mentioned, there was no observed impact on its response to autobiographical

471 memories (Carhart-Harris et al. 2014). While activation-based analyses deserve continued

472 attention in future studies to rectify these inconsistencies, functional connectivity is a

473 complimentary approach we can use to extract additional information from fMRI.

474

In a task-free setting, amygdala activity has been found to be anti-correlated with activity in areas involved in effortful regulation of affect, including the precuneus (Roy et al. 2009; Zhang and Li 2012). In healthy adults, amygdala-precuneus functional connectivity increases following the acute exposure to social stress (Veer et al. 2011, 2). This functional connection has been implicated in mood disorders including depression (Cullen et al. 2014; K. D. Young et al. 2018;

MDMA-AT Neural Response

480	Wei et al. 2018; Feurer et al. 2021; Peng et al. 2020), bipolar disorder (Stoddard et al. 2015;
481	Singh et al. 2015) and anxiety (Strawn et al. 2012; Toazza et al. 2016), childhood emotional
482	maltreatment (Werff et al. 2013), and PTSD (Nicholson et al. 2015; Bluhm et al. 2009; R. A.
483	Lanius et al. 2010). One study found adults who experienced childhood emotional maltreatment
484	show increased (decreased magnitude negative) connectivity between the amygdala and
485	precuneus compared to controls (Werff et al. 2013), and another found PTSD patients with
486	dissociative sub-type had increased connectivity compared to PTSD patients without dissociative
487	sub-type (Nicholson et al. 2015). Here, we find a strong, significant correlation between pre- to
488	post-therapy decreases in right amygdala-precuneus functional connectivity during neutral
489	scripts and pre- to post-therapy decreases in CAPS-IV. Attenuated correlation between the
490	activity patterns of these two regions at follow-up possibly suggests a decreased intensity of
491	recalled events, less 're-experiencing', or reduced negative affect.
492	
493	It is worth noting here that increased amygdala-precuneus functional connectivity during both
494	rest and positive autobiographical memory recall was found to correlate with improved

495

496 activation (K. D. Young et al. 2018). Depression is characterized by decreased arousal

497 (depressed mood) and diminished positive affect, therefore these findings may be reflective of an

depressive symptoms in adults using real-time fMRI neurofeedback targeting amygdala

498 increased emotional response to positive memories that is associated with symptom

499 improvement (Dunn et al. 2020). However, another study in adolescents found that those with

500 depression had greater amygdala-precuneus RSFC compared to healthy controls (Cullen et al.

501 2014), so replication is necessary. It seems likely that this functional connection is relevant to

502 cognitive affect in mood disorders, however more research is needed to determine if these

MDMA-AT Neural Response

503	findings are reflective of differences in depression and PTSD, or the context in which the study
504	populations were being imaged (i.e. studying processes and tasks related positive affect in the
505	case of depression and negative affect in the case of PTSD). Considering the co-morbidity of
506	depression and PTSD (Brady et al. 2000), amygdala-precuneus functional connectivity may
507	deserve increased attention in future studies.
508	
509	Also of interest were the significant correlations found between reduction in symptoms of
510	dissociation and changes in task functional connectivity. During neutral memory audio listening,
511	the reduction of left hippocampus to both left motor (pre- and post-central) gyri functional
512	connectivity correlated with reduction in dissociative symptoms. These two functional
513	connections appear to be higher in cases of trait anxiety (Yang et al. 2017). Lastly, MDMA
514	acutely alters insula functional connectivity (Walpola et al. 2017), a region implicated in anxiety
515	(Etkin and Wager 2007). Baur et al. (2013) provided evidence that amygdala-insula functional
516	connectivity indexes individual differences in state anxiety. Here, we find that reductions in right
517	amygdala-insula functional connectivity during trauma audio listening after MDMA-AT
518	correlates with reductions in dissociative symptoms, possibly relating to reduced anxiety or
519	dissociation during traumatic memory recall after treatment.
520	PTSD is characterized by decreased fear extinction in response to trauma-related stimuli. One
521	possible mechanism through which MDMA-AT operates is enhanced reconsolidation and/or fear
521	possible international unough which with $MDMA-AT$ operates is childred reconsolidation and/or real
522	extinction processes (Feduccia and Mithoeter 2018). Several studies with MDMA implicate
523	reconsolidation or fear extinction processes, and while it is currently unclear whether MDMA
524	acts on only one or both, it is important to note that the two interact (Suzuki et al. 2004). Rodent

525 models have demonstrated that the administration of MDMA prior to extinction learning

MDMA-AT Neural Response

526	enhances post-acute extinction retention and this effect is blocked by acute and chronic treatment
527	with a serotonin transporter inhibitor (M. B. Young et al. 2015; B. Young et al. 2017). Hake et
528	al. (2019) found that MDMA administered during extinction learning phases did not enhance
529	fear extinction memory, while MDMA administration during reconsolidation phases resulted in
530	prolonged reductions in conditioned fear. In addition, MDMA administered prior to trauma-cue
531	exposure (reconsolidation phase) in rodents resulted in reduced stress-related behavioral
532	responses 7 days later (Arluk et al. 2022). A randomized, controlled clinical trial in healthy
533	humans found that those who were administered MDMA (100 mg) prior to extinction learning
534	showed a higher rate of total extinction retention 48 hours later compared to the placebo group
535	(Maples-Keller et al. 2022). Doss et al. (2018) found that 1 mg/kg of MDMA in healthy humans
536	attenuated the encoding and retrieval of salient details from positive and negative stimuli (but not
537	neutral stimuli), suggesting an ability for MDMA to alter emotional memory representation.
538	Interestingly, a fMRI study in healthy humans found decreased activation in the precuneus/PCC
539	during fear extinction learning (Ridderbusch et al. 2021), regions highlighted by our present
540	study and others in PTSD (Garrett et al. 2019; Ke et al. 2016).

541 **LIMITATIONS**

The small sample size of the present study and the lack of a control population (e.g. traumaexposed controls) may decrease the generalizability of these findings. The trial design was placebo-controlled for dose-response (low, medium, and high), however, the follow-up scans used in this study were after the breaking of the blind and dose cross-over (low/medium to high) had occurred. For neuroimaging studies, comparisons with control populations are helpful for contextualizing longitudinal changes in brain response and provide information about whether changes in patient populations represent an abnormal response being restored to normality or a

MDMA-AT Neural Response

549	compensatory mechanism. In addition, multi-point imaging of healthy control or non-treatment
550	(placebo) groups allow for the quantification of test-retest variability.
551	
552	Here it must be discussed that PTSD is a disorder exhibiting at least two major sub-types with
553	characteristically opposing phenomenological and physiological responses to symptom
554	provocation, which may explain inconsistencies in the PTSD neurobiology literature (van
555	Huijstee and Vermetten 2018). In addition to sub-type heterogeneity, males and females with
556	PTSD may also differ in their neural responses (Helpman et al. 2021). Limited by our sample
557	size, we did not investigate these sub-groups in this study.
558	
559	The accepted standard for assessing PTSD severity is the Clinician-Administered PTSD Scale
560	(Blake et al. 1990). Specifically, CAPS-IV was used in this study. CAPS-IV involves an hour-
561	long semi-structured interview with a clinician and, though comprehensive, faces limitations. In
562	their baseline CAPS-IV assessment, and subsequently thereafter, patients were asked to refer to
563	an index trauma that was measured throughout the study. This may present an issue in accurately
564	assessing global PTSD severity if an adjacent or un-related trauma surfaces during therapy and
565	becomes the prominent driver of their symptoms. These issues, combined with difficulty in
566	blinding and expectancy effects, present additional challenges in accurately mapping fMRI
567	metrics to clinical outcomes. At the same time, these challenges motivate the need to improve
568	our ability to detect biomarkers of PTSD to accompany psychological indexes.
569	
570	The task design used in this study examined differences in brain response to personalized audio
571	scripts generated from narrations of traumatic and mundane (neutral) memories. Many different

MDMA-AT Neural Response

572	stimuli have been used in fMRI studies of PTSD (R. A. Lanius et al. 2006; Sartory et al. 2013;
573	Patel et al. 2012), each providing its own unique advantages and disadvantages. Our present
574	design optimizes personal relevance of the stimuli; however, this has the consequence of
575	presenting each subject with a different set of stimuli, whereby brain responses within each block
576	are not time-locked across participants. Also, it has previously been shown that PTSD survivors
577	take longer to retrieve unrelated autobiographical information when listening to taped imagery
578	scripts of their traumatic memories (Kleim, Wallott, and Ehlers 2008). This suggests the
579	possibility that those with the most severe PTSD will take the longest to cognitively transition to
580	the neutral block from the trauma block. If this is true, then there would perhaps be an inverse-
581	"U" relationship between PTSD severity and contrast between the trauma and neutral conditions,
582	if the blocks are not spaced far enough apart to allow adequate time for patients to return to a
583	baseline level of cognitive functioning.
584	

585 Finally, the pre-specified aim of this study was to estimate longitudinal (baseline to 2-months 586 after final MDMA session) changes in ROI response to traumatic audio scripts. Between the start 587 of data collection and analysis, new literature emerged (Carhart-Harris et al. 2015) implicating 588 amygdala-hippocampus RSFC as a potential target of MDMA-AT, compelling us to expand our 589 analysis beyond the pre-specified aims.

590

591 CONCLUSION

We report functional brain changes associated with MDMA-AT in participants with PTSD. We provide further evidence that MDMA-AT may act through strengthening the RSFC between the amygdala and hippocampus, a connection which is weaker in PTSD populations (Sripada et al.

MDMA-AT Neural Response

595	2012) and increased acutely by MDMA in healthy volunteers (Carhart-Harris et al. 2015). We
596	also provide preliminary evidence that MDMA-AT alters amygdala and precuneus response
597	during symptom provocation. These regions, associated with fear response and self-referential
598	processing, respectively, are commonly found to be hyperactive in PTSD patients (Sartory et al.
599	2013; Patel et al. 2012). However, the reduction of right amygdala-precuneus functional
600	connectivity co-varying with symptom reduction in PTSD is a novel finding. More research is
601	necessary to confirm this result and determine if this is an effect specific to MDMA-AT, or if it
602	would be found in other longitudinal treatment cohorts as well.
603	
604	END OF MANUSCRIPT
605	

MDMA-AT Neural Response

REFERENCES

- Arluk, Shira, Michael A. Matar, Lior Carmi, Oded Arbel, Joseph Zohar, Doron Todder, and Hagit Cohen. 2022. "MDMA Treatment Paired with a Trauma-Cue Promotes Adaptive Stress Responses in a Translational Model of PTSD in Rats." *Translational Psychiatry* 12 (1): 1–11. https://doi.org/10.1038/s41398-022-01952-8.
- Baur, Volker, Jürgen Hänggi, Nicolas Langer, and Lutz Jäncke. 2013. "Resting-State Functional and Structural Connectivity within an Insula-Amygdala Route Specifically Index State and Trait Anxiety." *Biological Psychiatry* 73 (1): 85–92. https://doi.org/10.1016/j.biopsych.2012.06.003.

Beck, A. T., R. A. Steer, R. Ball, and W. Ranieri. 1996. "Comparison of Beck Depression Inventories -IA and -II in Psychiatric Outpatients." *Journal of Personality Assessment* 67 (3): 588–97. https://doi.org/10.1207/s15327752jpa6703_13.

- Bedi, Gillinder, K. Luan Phan, Mike Angstadt, and Harriet de Wit. 2009. "Effects of MDMA on Sociability and Neural Response to Social Threat and Social Reward." *Psychopharmacology* 207 (1): 73–83. https://doi.org/10.1007/s00213-009-1635-z.
- Benjamini, Yoav, and Yosef Hochberg. 1995. "Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing." *Journal of the Royal Statistical Society. Series B (Methodological)* 57 (1): 289–300.
- Blake, Dudley, Frank Weathers, LN Nagy, D. Kaloupek, G. Klauminzer, Dennis Charney, and Terence Keane. 1990. "A Clinician Rating Scale for Assessing Current and Lifetime PTSD: The CAPS-1." *Behav. Ther.* 18 (January).
- Bluhm, Robyn L., Peter C. Williamson, Elizabeth A. Osuch, Paul A. Frewen, Todd K. Stevens, Kristine Boksman, Richard W. J. Neufeld, Jean Théberge, and Ruth A. Lanius. 2009.
 "Alterations in Default Network Connectivity in Posttraumatic Stress Disorder Related to Early-Life Trauma." *Journal of Psychiatry and Neuroscience* 34 (3): 187–94.
- Brady, Kathleen T, Therese Killeen, Tim Brewerton, and Sylvia Lucerini. 2000. "Comorbidity of Psychiatric Disorders and Posttraumatic Stress Disorder." *J Clin Psychiatry* 61: 11.
- Bremner, J. Douglas, Eric Vermetten, Christian Schmahl, Viola Vaccarino, Meena Vythilingam, Nadeem Afzal, Christian Grillon, and Dennis S. Charney. 2005. "Positron Emission Tomographic Imaging of Neural Correlates of a Fear Acquisition and Extinction Paradigm in Women with Childhood Sexual-Abuse-Related Post-Traumatic Stress Disorder." *Psychological Medicine* 35 (6): 791–806. https://doi.org/10.1017/S0033291704003290.
- Buysse, D. J., C. F. Reynolds, T. H. Monk, S. R. Berman, and D. J. Kupfer. 1989. "The Pittsburgh Sleep Quality Index: A New Instrument for Psychiatric Practice and Research." *Psychiatry Research* 28 (2): 193–213. https://doi.org/10.1016/0165-1781(89)90047-4.
- Carhart-Harris, R. L., M. B. Wall, D. Erritzoe, M. Kaelen, B. Ferguson, I. De Meer, M. Tanner, et al. 2014. "The Effect of Acutely Administered MDMA on Subjective and BOLD-FMRI Responses to Favourite and Worst Autobiographical Memories." *International Journal of Neuropsychopharmacology* 17 (4): 527–40. https://doi.org/10.1017/S1461145713001405.
- Carhart-Harris, Robin L., Kevin Murphy, Robert Leech, David Erritzoe, Matthew B. Wall, Bart Ferguson, Luke T.J. Williams, et al. 2015. "The Effects of Acutely Administered 3,4-Methylenedioxymethamphetamine on Spontaneous Brain Function in Healthy Volunteers

MDMA-AT Neural Response

Measured with Arterial Spin Labeling and Blood Oxygen Level–Dependent Resting State Functional Connectivity." *Biological Psychiatry* 78 (8): 554–62. https://doi.org/10.1016/j.biopsych.2013.12.015.

- Carlson, Eve Bernstein, and Frank W. Putnam. 1993. "An Update on the Dissociative Experiences Scale." *Dissociation: Progress in the Dissociative Disorders* 6 (1): 16–27.
- Cauda, Franco, Giuliano Geminiani, Federico D'Agata, Katiuscia Sacco, Sergio Duca, Andrew P. Bagshaw, and Andrea E. Cavanna. 2010. "Functional Connectivity of the Posteromedial Cortex." *PLoS ONE* 5 (9): e13107. https://doi.org/10.1371/journal.pone.0013107.
- Cavanna, Andrea E., and Michael R. Trimble. 2006. "The Precuneus: A Review of Its Functional Anatomy and Behavioural Correlates." *Brain: A Journal of Neurology* 129 (Pt 3): 564– 83. https://doi.org/10.1093/brain/awl004.
- Chiao, Joan Y., Tetsuya Iidaka, Heather L. Gordon, Junpei Nogawa, Moshe Bar, Elissa Aminoff, Norihiro Sadato, and Nalini Ambady. 2008. "Cultural Specificity in Amygdala Response to Fear Faces." *Journal of Cognitive Neuroscience* 20 (12): 2167–74. https://doi.org/10.1162/jocn.2008.20151.
- Cullen, Kathryn R., Melinda K. Westlund, Bonnie Klimes-Dougan, Bryon A. Mueller, Alaa Houri, Lynn E. Eberly, and Kelvin O. Lim. 2014. "Abnormal Amygdala Resting-State Functional Connectivity in Adolescent Depression." *JAMA Psychiatry* 71 (10): 1138–47. https://doi.org/10.1001/jamapsychiatry.2014.1087.
- Dale, A. M., B. Fischl, and M. I. Sereno. 1999. "Cortical Surface-Based Analysis. I. Segmentation and Surface Reconstruction." *NeuroImage* 9 (2): 179–94. https://doi.org/10.1006/nimg.1998.0395.
- Desikan, Rahul S., Florent Ségonne, Bruce Fischl, Brian T. Quinn, Bradford C. Dickerson, Deborah Blacker, Randy L. Buckner, et al. 2006. "An Automated Labeling System for Subdividing the Human Cerebral Cortex on MRI Scans into Gyral Based Regions of Interest." *NeuroImage* 31 (3): 968–80. https://doi.org/10.1016/j.neuroimage.2006.01.021.
- Doss, Manoj K., Jessica Weafer, David A. Gallo, and Harriet de Wit. 2018. "MDMA Impairs Both the Encoding and Retrieval of Emotional Recollections." *Neuropsychopharmacology* 43 (4): 791–800. https://doi.org/10.1038/npp.2017.171.
- Dunn, Barnaby D., Ramaris E. German, Gabi Khazanov, Colin Xu, Steven D. Hollon, and Robert J. DeRubeis. 2020. "Changes in Positive and Negative Affect During Pharmacological Treatment and Cognitive Therapy for Major Depressive Disorder: A Secondary Analysis of Two Randomized Controlled Trials." *Clinical Psychological Science* 8 (1): 36–51. https://doi.org/10.1177/2167702619863427.
- Ehlers, Anke. 2010. "Understanding and Treating Unwanted Trauma Memories in Posttraumatic Stress Disorder." *Zeitschrift Für Psychologie / Journal of Psychology* 218 (2): 141–45. https://doi.org/10.1027/0044-3409/a000021.
- Etkin, Amit, and Tor D. Wager. 2007. "Functional Neuroimaging of Anxiety: A Meta-Analysis of Emotional Processing in PTSD, Social Anxiety Disorder, and Specific Phobia." *American Journal of Psychiatry* 164 (10): 1476–88. https://doi.org/10.1176/appi.ajp.2007.07030504.
- Feduccia, Allison A., and Michael C. Mithoefer. 2018. "MDMA-Assisted Psychotherapy for PTSD: Are Memory Reconsolidation and Fear Extinction Underlying Mechanisms?" *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 84 (June): 221–28. https://doi.org/10.1016/j.pnpbp.2018.03.003.

MDMA-AT Neural Response

- Feurer, Cope, Jagan Jimmy, Fini Chang, Scott A. Langenecker, K. Luan Phan, Olusola Ajilore, and Heide Klumpp. 2021. "Resting State Functional Connectivity Correlates of Rumination and Worry in Internalizing Psychopathologies." *Depression and Anxiety* 38 (5): 488–97. https://doi.org/10.1002/da.23142.
- Friston, K. J., S. Williams, R. Howard, R. S. Frackowiak, and R. Turner. 1996. "Movement-Related Effects in FMRI Time-Series." *Magnetic Resonance in Medicine* 35 (3): 346–55. https://doi.org/10.1002/mrm.1910350312.
- Garrett, Amy, Judith A. Cohen, Sanno Zack, Victor Carrion, Booil Jo, Joseph Blader, Alexis Rodriguez, Thomas J. Vanasse, Allan L. Reiss, and W. Stewart Agras. 2019.
 "Longitudinal Changes in Brain Function Associated with Symptom Improvement in Youth with PTSD." *Journal of Psychiatric Research* 114 (July): 161–69. https://doi.org/10.1016/j.jpsychires.2019.04.021.
- Goetter, Elizabeth M., Eric Bui, Rebecca A. Ojserkis, Rebecca J. Zakarian, Rebecca Weintraub Brendel, and Naomi M. Simon. 2015. "A Systematic Review of Dropout From Psychotherapy for Posttraumatic Stress Disorder Among Iraq and Afghanistan Combat Veterans." *Journal of Traumatic Stress* 28 (5): 401–9. https://doi.org/10.1002/jts.22038.
- Guze, Samuel B. 1995. "Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV)." *American Journal of Psychiatry* 152 (8): 1228–1228. https://doi.org/10.1176/ajp.152.8.1228.
- Hake, Holly S., Jazmyne K. P. Davis, River R. Wood, Margaret K. Tanner, Esteban C. Loetz, Anais Sanchez, Mykola Ostrovskyy, et al. 2019. "3,4-Methylenedioxymethamphetamine (MDMA) Impairs the Extinction and Reconsolidation of Fear Memory in Rats." *Physiology & Behavior* 199 (February): 343–50. https://doi.org/10.1016/j.physbeh.2018.12.007.
- Harnett, Nathaniel G., Adam M. Goodman, and David C. Knight. 2020. "PTSD-Related Neuroimaging Abnormalities in Brain Function, Structure, and Biochemistry." *Experimental Neurology* 330 (August): 113331. https://doi.org/10.1016/j.expneurol.2020.113331.
- Helpman, Liat, Xi Zhu, Sigal Zilcha-Mano, Benjamin Suarez-Jimenez, Amit Lazarov, Bret Rutherford, and Yuval Neria. 2021. "Reversed Patterns of Resting State Functional Connectivity for Females vs. Males in Posttraumatic Stress Disorder." *Neurobiology of Stress* 15 (November): 100389. https://doi.org/10.1016/j.ynstr.2021.100389.
- Huijstee, Jytte van, and Eric Vermetten. 2018. "The Dissociative Subtype of Post-Traumatic Stress Disorder: Research Update on Clinical and Neurobiological Features." *Current Topics in Behavioral Neurosciences* 38: 229–48. https://doi.org/10.1007/7854_2017_33.
- Jerome, Lisa, Allison A. Feduccia, Julie B. Wang, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, Michael C. Mithoefer, and Rick Doblin. 2020. "Long-Term Follow-up Outcomes of MDMA-Assisted Psychotherapy for Treatment of PTSD: A Longitudinal Pooled Analysis of Six Phase 2 Trials." *Psychopharmacology* 237 (8): 2485–97. https://doi.org/10.1007/s00213-020-05548-2.
- Ke, Jun, Li Zhang, Rongfeng Qi, Weihui Li, Cailan Hou, Yuan Zhong, Zhong He, Lingjiang Li, and Guangming Lu. 2016. "A Longitudinal FMRI Investigation in Acute Post-Traumatic Stress Disorder (PTSD)." Acta Radiologica 57 (11): 1387–95. https://doi.org/10.1177/0284185115585848.
- Kleim, Birgit, Franziska Wallott, and Anke Ehlers. 2008. "Are Trauma Memories Disjointed from Other Autobiographical Memories in Posttraumatic Stress Disorder? An

MDMA-AT Neural Response

Experimental Investigation." *Behavioural and Cognitive Psychotherapy* 36 (2): 221–34. https://doi.org/10.1017/S1352465807004080.

- Lanius, R. A., R. L. Bluhm, N. J. Coupland, K. M. Hegadoren, B. Rowe, J. Théberge, R. W. J. Neufeld, P. C. Williamson, and M. Brimson. 2010. "Default Mode Network Connectivity as a Predictor of Post-Traumatic Stress Disorder Symptom Severity in Acutely Traumatized Subjects." *Acta Psychiatrica Scandinavica* 121 (1): 33–40. https://doi.org/10.1111/j.1600-0447.2009.01391.x.
- Lanius, R. A., R. Bluhm, U. Lanius, and C. Pain. 2006. "A Review of Neuroimaging Studies in PTSD: Heterogeneity of Response to Symptom Provocation." *Journal of Psychiatric Research* 40 (8): 709–29. https://doi.org/10.1016/j.jpsychires.2005.07.007.
- Lanius, R. A., P. C. Williamson, M. Densmore, K. Boksman, M. A. Gupta, R. W. Neufeld, J. S. Gati, and R. S. Menon. 2001. "Neural Correlates of Traumatic Memories in Posttraumatic Stress Disorder: A Functional MRI Investigation." *The American Journal of Psychiatry* 158 (11): 1920–22. https://doi.org/10.1176/appi.ajp.158.11.1920.
- Lanius, Ruth A., Peter C. Williamson, Kristine Boksman, Maria Densmore, Madhulika Gupta, Richard W. J. Neufeld, Joseph S. Gati, and Ravi S. Menon. 2002. "Brain Activation during Script-Driven Imagery Induced Dissociative Responses in PTSD: A Functional Magnetic Resonance Imaging Investigation." *Biological Psychiatry* 52 (4): 305–11. https://doi.org/10.1016/s0006-3223(02)01367-7.
- LeDoux, Joseph. 2003. "The Emotional Brain, Fear, and the Amygdala." *Cellular and Molecular Neurobiology* 23 (4): 727–38. https://doi.org/10.1023/A:1025048802629.
- Lewis, Catrin, Neil P. Roberts, Samuel Gibson, and Jonathan I. Bisson. 2020. "Dropout from Psychological Therapies for Post-Traumatic Stress Disorder (PTSD) in Adults: Systematic Review and Meta-Analysis." *European Journal of Psychotraumatology* 11 (1): 1709709. https://doi.org/10.1080/20008198.2019.1709709.
- Liberzon, Israel, Stephan F. Taylor, Richard Amdur, Tara D. Jung, Kenneth R. Chamberlain, Satoshi Minoshima, Robert A. Koeppe, and Lorraine M. Fig. 1999. "Brain Activation in PTSD in Response to Trauma-Related Stimuli." *Biological Psychiatry* 45 (7): 817–26. https://doi.org/10.1016/S0006-3223(98)00246-7.
- Liddell, Belinda J., and Laura Jobson. 2016. "The Impact of Cultural Differences in Self-Representation on the Neural Substrates of Posttraumatic Stress Disorder." *European Journal of Psychotraumatology* 7 (1): 30464. https://doi.org/10.3402/ejpt.v7.30464.
- Maddock, R. J. 1999. "The Retrosplenial Cortex and Emotion: New Insights from Functional Neuroimaging of the Human Brain." *Trends in Neurosciences* 22 (7): 310–16. https://doi.org/10.1016/s0166-2236(98)01374-5.
- Maples-Keller, Jessica L., Seth D. Norrholm, Mark Burton, Collin Reiff, Callan Coghlan, Tanja Jovanovic, Carly Yasinski, et al. 2022. "A Randomized Controlled Trial of 3,4-Methylenedioxymethamphetamine (MDMA) and Fear Extinction Retention in Healthy Adults." *Journal of Psychopharmacology (Oxford, England)*, February, 2698811211069124. https://doi.org/10.1177/02698811211069124.
- Mitchell, Jennifer M., Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman, Kelly Parker-Guilbert, Marcela Ot'alora G., et al. 2021. "MDMA-Assisted Therapy for Severe PTSD: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study." *Nature Medicine* 27 (6): 1025–33. https://doi.org/10.1038/s41591-021-01336-3.
- Mithoefer, Michael C., Allison A. Feduccia, Lisa Jerome, Anne Mithoefer, Mark Wagner, Zach Walsh, Scott Hamilton, Berra Yazar-Klosinski, Amy Emerson, and Rick Doblin. 2019.

MDMA-AT Neural Response

"MDMA-Assisted Psychotherapy for Treatment of PTSD: Study Design and Rationale for Phase 3 Trials Based on Pooled Analysis of Six Phase 2 Randomized Controlled Trials." *Psychopharmacology* 236 (9): 2735–45. https://doi.org/10.1007/s00213-019-05249-5.

- Mithoefer, Michael C., Ann T. Mithoefer, Allison A. Feduccia, Lisa Jerome, Mark Wagner, Joy Wymer, Julie Holland, et al. 2018. "3,4-Methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy for Post-Traumatic Stress Disorder in Military Veterans, Firefighters, and Police Officers: A Randomised, Double-Blind, Dose-Response, Phase 2 Clinical Trial." *The Lancet Psychiatry* 5 (6): 486–97. https://doi.org/10.1016/S2215-0366(18)30135-4.
- Mithoefer, Michael C., Mark T. Wagner, Ann T. Mithoefer, Lisa Jerome, and Rick Doblin. 2011.
 "The Safety and Efficacy of {+/-}3,4-Methylenedioxymethamphetamine-Assisted Psychotherapy in Subjects with Chronic, Treatment-Resistant Posttraumatic Stress Disorder: The First Randomized Controlled Pilot Study." *Journal of Psychopharmacology (Oxford, England)* 25 (4): 439–52. https://doi.org/10.1177/0269881110378371.
- Nicholson, Andrew A., Maria Densmore, Paul A. Frewen, Jean Théberge, Richard WJ Neufeld, Margaret C. McKinnon, and Ruth A. Lanius. 2015. "The Dissociative Subtype of Posttraumatic Stress Disorder: Unique Resting-State Functional Connectivity of Basolateral and Centromedial Amygdala Complexes." *Neuropsychopharmacology* 40 (10): 2317–26. https://doi.org/10.1038/npp.2015.79.
- Patel, Ronak, R. Nathan Spreng, Lisa M. Shin, and Todd A. Girard. 2012. "Neurocircuitry Models of Posttraumatic Stress Disorder and beyond: A Meta-Analysis of Functional Neuroimaging Studies." *Neuroscience & Biobehavioral Reviews* 36 (9): 2130–42. https://doi.org/10.1016/j.neubiorev.2012.06.003.
- Peng, Xiaoling, Way K. W. Lau, Chanyu Wang, Lingfang Ning, and Ruibin Zhang. 2020. "Impaired Left Amygdala Resting State Functional Connectivity in Subthreshold Depression Individuals." *Scientific Reports* 10 (1): 17207. https://doi.org/10.1038/s41598-020-74166-x.
- Pitman, Roger K., Ann M. Rasmusson, Karestan C. Koenen, Lisa M. Shin, Scott P. Orr, Mark W. Gilbertson, Mohammed R. Milad, and Israel Liberzon. 2012. "Biological Studies of Post-Traumatic Stress Disorder." *Nature Reviews Neuroscience* 13 (11): 769–87. https://doi.org/10.1038/nrn3339.
- Rauch, Scott L., Lisa M. Shin, and Elizabeth A. Phelps. 2006. "Neurocircuitry Models of Posttraumatic Stress Disorder and Extinction: Human Neuroimaging Research--Past, Present, and Future." *Biological Psychiatry* 60 (4): 376–82. https://doi.org/10.1016/j.biopsych.2006.06.004.
- Ravindran, Lakshmi N., and Murray B. Stein. 2009. "Pharmacotherapy of PTSD: Premises, Principles, and Priorities." *Brain Research* 1293 (October): 24–39. https://doi.org/10.1016/j.brainres.2009.03.037.
- Ridderbusch, Isabelle C., Adrian Wroblewski, Yunbo Yang, Jan Richter, Maike Hollandt, Alfons O. Hamm, Hans-Ulrich Wittchen, et al. 2021. "Neural Adaptation of Cingulate and Insular Activity during Delayed Fear Extinction: A Replicable Pattern across Assessment Sites and Repeated Measurements." *NeuroImage* 237 (August): 118157. https://doi.org/10.1016/j.neuroimage.2021.118157.

MDMA-AT Neural Response

- Roy, Amy Krain, Zarrar Shehzad, Daniel S. Margulies, A. M. Clare Kelly, Lucina Q. Uddin, Kristin Gotimer, Bharat B. Biswal, F. Xavier Castellanos, and Michael P. Milham. 2009.
 "Functional Connectivity of the Human Amygdala Using Resting State FMRI." *NeuroImage* 45 (2): 614–26. https://doi.org/10.1016/j.neuroimage.2008.11.030.
- Sartory, Gudrun, Jan Cwik, Helge Knuppertz, Benjamin Schürholt, Morena Lebens, Rüdiger J. Seitz, and Ralf Schulze. 2013. "In Search of the Trauma Memory: A Meta-Analysis of Functional Neuroimaging Studies of Symptom Provocation in Posttraumatic Stress Disorder (PTSD)." *PloS One* 8 (3): e58150. https://doi.org/10.1371/journal.pone.0058150.
- Sestieri, Carlo, Maurizio Corbetta, Gian Luca Romani, and Gordon L. Shulman. 2011. "Episodic Memory Retrieval, Parietal Cortex, and the Default Mode Network: Functional and Topographic Analyses." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 31 (12): 4407–20. https://doi.org/10.1523/JNEUROSCI.3335-10.2011.
- Singh, Manpreet K., Ryan G. Kelley, Kiki D. Chang, and Ian H. Gotlib. 2015. "Intrinsic Amygdala Functional Connectivity in Youth With Bipolar I Disorder." *Journal of the American Academy of Child & Adolescent Psychiatry* 54 (9): 763–70. https://doi.org/10.1016/j.jaac.2015.06.016.
- Smith, Stephen M., Mark Jenkinson, Mark W. Woolrich, Christian F. Beckmann, Timothy E. J. Behrens, Heidi Johansen-Berg, Peter R. Bannister, et al. 2004. "Advances in Functional and Structural MR Image Analysis and Implementation as FSL." *NeuroImage* 23 Suppl 1: S208-219. https://doi.org/10.1016/j.neuroimage.2004.07.051.
- Smith, Stephen M., and Thomas E. Nichols. 2009. "Threshold-Free Cluster Enhancement: Addressing Problems of Smoothing, Threshold Dependence and Localisation in Cluster Inference." *NeuroImage* 44 (1): 83–98.
 - https://doi.org/10.1016/j.neuroimage.2008.03.061.
- Spreng, R. Nathan, Raymond A. Mar, and Alice S. N. Kim. 2009. "The Common Neural Basis of Autobiographical Memory, Prospection, Navigation, Theory of Mind, and the Default Mode: A Quantitative Meta-Analysis." *Journal of Cognitive Neuroscience* 21 (3): 489– 510. https://doi.org/10.1162/jocn.2008.21029.
- Sripada, Rebecca, Anthony King, Sarah Garfinkel, Xin Wang, Chandra Sripada, Robert Welsh, and Israel Liberzon. 2012. "Altered Resting-State Amygdala Functional Connectivity in Men with Posttraumatic Stress Disorder." *Journal of Psychiatry & Neuroscience* 37 (4): 241–49. https://doi.org/10.1503/jpn.110069.
- Stoddard, Joel, Derek Hsu, Richard C. Reynolds, Melissa A. Brotman, Monique Ernst, Daniel S. Pine, Ellen Leibenluft, and Daniel P. Dickstein. 2015. "Aberrant Amygdala Intrinsic Functional Connectivity Distinguishes Youths with Bipolar Disorder from Those with Severe Mood Dysregulation." *Psychiatry Research: Neuroimaging* 231 (2): 120–25. https://doi.org/10.1016/j.pscychresns.2014.11.006.
- Strawn, Jeffrey R., Samantha M. Bitter, Wade A. Weber, Wen-Jang Chu, Rachel M. Whitsel, Caleb Adler, Michel A. Cerullo, James Eliassen, Stephen M. Strakowski, and Melissa P. DelBello. 2012. "Neurocircuitry of Generalized Anxiety Disorder in Adolescents: A Pilot Functional Neuroimaging and Functional Connectivity Study." *Depression and Anxiety* 29 (11): 939–47. https://doi.org/10.1002/da.21961.
- Suzuki, Akinobu, Sheena A. Josselyn, Paul W. Frankland, Shoichi Masushige, Alcino J. Silva, and Satoshi Kida. 2004. "Memory Reconsolidation and Extinction Have Distinct

MDMA-AT Neural Response

Temporal and Biochemical Signatures." *Journal of Neuroscience* 24 (20): 4787–95. https://doi.org/10.1523/JNEUROSCI.5491-03.2004.

- Svoboda, Eva, Margaret C. McKinnon, and Brian Levine. 2006. "The Functional Neuroanatomy of Autobiographical Memory: A Meta-Analysis." *Neuropsychologia* 44 (12): 2189–2208. https://doi.org/10.1016/j.neuropsychologia.2006.05.023.
- Tedeschi, R. G., and L. G. Calhoun. 1996. "The Posttraumatic Growth Inventory: Measuring the Positive Legacy of Trauma." *Journal of Traumatic Stress* 9 (3): 455–71. https://doi.org/10.1007/BF02103658.
- Toazza, Rudineia, Alexandre Rosa Franco, Augusto Buchweitz, Roberta Dalle Molle, Danitsa Marcos Rodrigues, Roberta Sena Reis, Amanda Brondani Mucellini, et al. 2016.
 "Amygdala-Based Intrinsic Functional Connectivity and Anxiety Disorders in Adolescents and Young Adults." *Psychiatry Research: Neuroimaging* 257 (November): 11–16. https://doi.org/10.1016/j.pscychresns.2016.09.010.
- VanElzakker, Michael B., Lindsay K. Staples-Bradley, and Lisa M. Shin. 2018. "The Neurocircuitry of Fear and PTSD." In *Sleep and Combat-Related Post Traumatic Stress Disorder*, edited by Eric Vermetten, Anne Germain, and Thomas C. Neylan, 111–25. New York, NY: Springer. https://doi.org/10.1007/978-1-4939-7148-0_10.
- Veer, Ilya M., Nicole Y. L. Oei, Philip Spinhoven, Mark A. van Buchem, Bernet M. Elzinga, and Serge A. R. B. Rombouts. 2011. "Beyond Acute Social Stress: Increased Functional Connectivity between Amygdala and Cortical Midline Structures." *NeuroImage* 57 (4): 1534–41. https://doi.org/10.1016/j.neuroimage.2011.05.074.
- Walpola, Ishan C., Timothy Nest, Leor Roseman, David Erritzoe, Amanda Feilding, David J. Nutt, and Robin L. Carhart-Harris. 2017. "Altered Insula Connectivity under MDMA." *Neuropsychopharmacology* 42 (11): 2152–62. https://doi.org/10.1038/npp.2017.35.
- Wang, Julie B., Jessica Lin, Leah Bedrosian, Allison Coker, Ilsa Jerome, Allison Feduccia, Alia Lilienstein, et al. 2021. "Scaling Up: Multisite Open-Label Clinical Trials of MDMA-Assisted Therapy for Severe Posttraumatic Stress Disorder." *Journal of Humanistic Psychology*, June, 00221678211023663. https://doi.org/10.1177/00221678211023663.
- Wei, Shengnan, Miao Chang, Ran Zhang, Xiaowei Jiang, Fei Wang, and Yanqing Tang. 2018. "Amygdala Functional Connectivity in Female Patients with Major Depressive Disorder with and without Suicidal Ideation." *Annals of General Psychiatry* 17 (1): 37. https://doi.org/10.1186/s12991-018-0208-0.
- Werff, S. J. A. van der, J. N. Pannekoek, I. M. Veer, M.-J. van Tol, A. Aleman, D. J. Veltman, F. G. Zitman, S. a. R. B. Rombouts, B. M. Elzinga, and N. J. A. van der Wee. 2013. "Resting-State Functional Connectivity in Adults with Childhood Emotional Maltreatment." *Psychological Medicine* 43 (9): 1825–36. https://doi.org/10.1017/S0033291712002942.
- Winkler, Anderson M., Gerard R. Ridgway, Matthew A. Webster, Stephen M. Smith, and Thomas E. Nichols. 2014. "Permutation Inference for the General Linear Model." *NeuroImage* 92 (May): 381–97. https://doi.org/10.1016/j.neuroimage.2014.01.060.
- Woolrich, Mark W., Timothy E. J. Behrens, Christian F. Beckmann, Mark Jenkinson, and Stephen M. Smith. 2004. "Multilevel Linear Modelling for FMRI Group Analysis Using Bayesian Inference." *NeuroImage* 21 (4): 1732–47. https://doi.org/10.1016/j.neuroimage.2003.12.023.

MDMA-AT Neural Response

- Yang, Yang, Fanlu Jia, Wai Ting Siok, and Li Hai Tan. 2017. "The Role of Anxiety in Stuttering: Evidence from Functional Connectivity." *Neuroscience* 346 (March): 216–25. https://doi.org/10.1016/j.neuroscience.2016.11.033.
- Young, Kymberly D., Greg J. Siegle, Masaya Misaki, Vadim Zotev, Raquel Phillips, Wayne C. Drevets, and Jerzy Bodurka. 2018. "Altered Task-Based and Resting-State Amygdala Functional Connectivity Following Real-Time FMRI Amygdala Neurofeedback Training in Major Depressive Disorder." *NeuroImage: Clinical* 17 (January): 691–703. https://doi.org/10.1016/j.nicl.2017.12.004.
- Young, M. B., R. Andero, K. J. Ressler, and L. L. Howell. 2015. "3,4-Methylenedioxymethamphetamine Facilitates Fear Extinction Learning." *Translational Psychiatry* 5 (9): e634–e634. https://doi.org/10.1038/tp.2015.138.
- Young, Matthew B., Seth D. Norrholm, Lara M. Khoury, Tanja Jovanovic, Sheila A.M. Rauch, Collin M. Reiff, Boadie W. Dunlop, Barbara O. Rothbaum, and Leonard L. Howell. 2017. "Inhibition of Serotonin Transporters Disrupts the Enhancement of Fear Memory Extinction by 3,4-Methylenedioxymethamphetamine (MDMA)." *Psychopharmacology* 234 (19): 2883–95. https://doi.org/10.1007/s00213-017-4684-8.
- Zhang, Sheng, and Chiang-shan R. Li. 2012. "Functional Connectivity Mapping of the Human Precuneus by Resting State FMRI." *NeuroImage* 59 (4): 3548–62. https://doi.org/10.1016/j.neuroimage.2011.11.023.